Collegium Pharmaceutical, Inc.
COLL · Price history
Price at last available close
$23.23
+$1.00 (+4.50%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Collegium Pharmaceutical, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse.
How they make money
Collegium Pharmaceutical is a biopharmaceutical company that generates revenue primarily through the commercialization of a portfolio of pain management medications and neuropsychiatry products. The company utilizes a specialized sales force to market these products to healthcare professionals and manages distribution through wholesale and pharmacy channels.
Products & services
The company's portfolio includes Jornay PM for ADHD, and pain management products including Xtampza ER, Belbuca, and the Nucynta franchise.
Brands & revenue mix
Differentiated treatment for ADHD and lead growth driver.
Separate brand revenue is not available in this research.Source
Extended-release pain management medication.
Separate brand revenue is not available in this research.Source
Licensed pain management product franchise.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company discloses that it is subject to risks related to customer concentration, as a significant portion of its revenue is derived from a limited number of wholesale distributors.
Suppliers, materials & equipment
- Patheon (Thermo Fisher Scientific) — Contract manufacturing organization for the production of Xtampza ER.Source
Business relationships & partnerships
Strengths
Sources
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly EPS turned negative at -0.46 versus 0.34 a year earlier.
Separate recurring operating losses from noncash or one-time charges, and check cash flow rather than interpreting negative EPS as a cash-outflow amount.
Quarterly net income turned from a profit to a loss versus the same quarter last year.
Identify the causes in the interim report and distinguish operating cash use from accounting charges. Prior profitability is not a guarantee of recovery.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
55
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
53
Fair
Financial Strength
34
Business Quality / Moat
84
Management
69
Growth Quality
32
Risk / Durability
36
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
64
Fully Valued
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
63/100
Building Historical Record
Model Score 63/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is mixed across its combined quality, valuation and risk inputs. Review the category scores to identify what is helping or hurting the result.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
- •Asset quality scores strongly
- •Valuation scores attractively
- •Recent buyback activity is present
- •Repurchase headline · Aug 13, 2026
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for COLL
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can COLL maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is COLL's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is COLL's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •Is COLL's valuation discount tied to a temporary concern or to a longer-term business risk?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of COLL's score?
Essential Investment Snapshot
Wall Street Score
55
Opportunity Score
64
Market Cap
$756.3M
P/E Ratio
14.3
EPS
$1.53
52-Week High
$50.79
52-Week Low
$21.62
Beta
0.72
Intrinsic Value
$58.91
Analyst Target
$48.50
Shares Outstanding
39.7M
Total Revenue
$808.2M
Total Debt
$857.8M
Dividend
No current dividend
Liquidation Value / Share
$7.86
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for COLL
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Repurchase headline · Aug 13, 2026
Collegium Announces $50 Million Accelerated Share Repurchase Program — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on COLL.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Leading portfolio of responsible pain management medications.
- +Growing neuropsychiatry business driven by Jornay PM.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Drug Manufacturers - Specialty & Generic industry.
- −Customer concentration.
- −Compliance with U.S. Drug Enforcement Agency regulations.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
58
Sep 17, 2026
Change
-2.9
points
Current Score
55
Oct 1, 2026
Category Changes
COLL decreased 2.9 points because some fundamentals weakened.
Projected Score
Projected Score
50
Projected Change
-5.4 points
Preliminary comparable-period financial changes suggest decline of approximately 5.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$23.23
Model Intrinsic Value
$58.91
Difference
−$35.67
-60.6% vs IV
Margin of Safety
60.6%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $808.2M | $780.6M | $631.4M | $566.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $323.1M | $317.3M | $254.1M | $240.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $485.1M | $463.3M | $377.3M | $326.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $239.8M | $276.2M | $183.0M | $159.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $326.6M | $276.2M | $207.4M | $159.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $586.6M | $401.0M | $341.7M | $308.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $158.5M | $187.1M | $169.9M | $167.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $161.9M | $82.3M | $74.0M | $83.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $77.7M | $92.6M | $98.6M | $75.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $29.8M | $29.7M | $29.4M | $27.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $47.9M | $62.9M | $69.2M | $48.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $1.53 | $1.98 | $2.14 | $1.60 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 32.46M | 31.71M | 32.27M | 33.74M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 32.46M | 39.70M | 40.42M | 41.79M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$199.9M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.46
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+3.5%
Cash Change
+10.3%
Margin Change
-13.9 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Margins contracted
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, cash levels. Pressure indicators included EPS growth, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 6.3%. EPS declined 235.3%. Cash increased 10.3%. Total debt increased 3.5%. Net income margin declined by 13.9 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - Specialty & GenericNews
COLL vs. DSNKY: Which Stock Is the Better Value Option?
Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut
Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Collegium to Participate in Upcoming Investor Conferences
Rumor Mill · COLL
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial